DexCom, Inc. (DXCM)
| Market Cap | 31.26B |
| Revenue (ttm) | 3.95B |
| Net Income (ttm) | 680.80M |
| Shares Out | 390.60M |
| EPS (ttm) | 1.67 |
| PE Ratio | 48.00 |
| Forward PE | 41.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,450,882 |
| Open | 75.47 |
| Previous Close | 75.82 |
| Day's Range | 75.47 - 81.51 |
| 52-Week Range | 62.34 - 142.00 |
| Beta | 1.13 |
| Analysts | Buy |
| Price Target | 98.00 (+22.44%) |
| Earnings Date | Feb 6, 2025 |
About DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into t... [Read more]
Financial Performance
In 2023, DexCom's revenue was $3.62 billion, an increase of 24.49% compared to the previous year's $2.91 billion. Earnings were $541.50 million, an increase of 58.70%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for DXCM stock is "Buy." The 12-month stock price forecast is $98.0, which is an increase of 22.44% from the latest price.
News
Diabetes Brands Dexcom, Ozempic, Mounjaro Drive Q3 Convergent TV Ad Engagement
NEW YORK--(BUSINESS WIRE)--EDO, the TV outcomes company, has released its Q3 2024 Diabetes Convergent TV Outcomes Report, providing critical insights into the diabetes category linear and streaming TV...
Dexcom's over-the-counter glucose monitor now offers users an AI summary of how sleep, meals and more impact sugar levels
Dexcom on Tuesday announced its first generative AI feature for its Stelo biosensor that gives users a personalized weekly report about their glucose. The company has been building a generative AI pla...
Dexcom Launches the First Generative AI Platform in Glucose Biosensing
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today it has launched a proprietary Generative AI (GenAI) platform, making Dexcom the first C...
Alberta Government Lifts Age Restrictions on Continuous Glucose Monitors (CGM) and Eligible Albertans With Type 1 or Type 2 Diabetes Can Now Access Dexcom G7 CGM
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing technology, is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) S...
DexCom: Brighter 2025 From Stelo Ramp
DexCom faces challenges in 2024 due to competition and missteps, but the long-term outlook for continuous glucose monitors remains strong. Q3 revenue grew only 2% y/y to $994.2 million, with temporary...
11 Ultra SWAN Bargains That Could Thrive As The Market Soars To Record Highs
The S&P is up 27% in 2024, including a 5.5% rally in November. The Euphoria index is at record highs, indicating investor sentiment is extremely bullish. While 2025 is likely to see much larger volati...
DexCom Pairs Its Glucose Monitor With Oura's Smart Ring
If you want to monitor your vital signs like an Olympic athlete, you should welcome a pact between glucose-monitor vendor DexCom and Oura smart rings.
Oura CEO on new partnership with Dexcom
Tom Hale, Oura CEO, joins 'Squawk Box' to discuss the company's new partnership with Dexcom, glucose monitors, and much more.
Smart ring maker Ōura valued at over $5 bln after Dexcom funding
Medical device maker Dexcom said on Tuesday it will invest $75 million in Ōura's latest funding round, valuing the smart ring maker at over $5 billion.
Dexcom and ŌURA Announce Strategic Partnership
SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, and ŌURA, maker of the world's leading smart ring, announced today a strategic partners...
Dexcom Helps People With Diabetes Take the First Step to Discover What They're Made Of on World Diabetes Day
SAN DIEGO--(BUSINESS WIRE)--This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first ste...
3 Top Stocks for Growth Investors to Buy Now
The undervalued stocks of these mid-sized companies with economic moats look attractive.
These Analysts Revise Their Forecasts On DexCom Following Q3 Results
DexCom, Inc. DXCM reported better-than-expected third-quarter results on Thursday.
DexCom Beats Earnings Expectations. Why the Stock Is Trading Lower.
DexCom's U.S. revenue declines 2% in the third quarter from a year earlier.
Capri, Coursera, DexCom And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Friday.
DexCom Growing Into Its Valuation, But Still No Bargain
DexCom's stock has declined 35% since my last bearish article, validating my "Sell" rating, though past bearish calls were incorrect as the stock previously doubled and tripled. Q3 results showed disa...
DexCom, Inc. (DXCM) Q3 2024 Earnings Call Transcript
DexCom, Inc. (NASDAQ:DXCM) Q3 2024 Earnings Call Transcript October 24, 2024 4:30 PM ET Company Participants Sean Christensen - VP, Finance and IR Kevin Sayer - President and CEO Jereme Sylvain - CFO...
Dexcom shares fall on slow revenue growth
Dexcom shares fell on Thursday after the company released third-quarter results that beat expectations but showed slow revenue growth. The company's revenue increased 2% from $975 million a year earli...
Dexcom beats estimates for third-quarter sales, reiterates annual forecast
Medical device maker Dexcom beat Wall Street estimates for third-quarter revenue on Thursday, helped by resilient demand for its continuous glucose monitors for diabetes patients.
Dexcom Reports Third Quarter 2024 Financial Results
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights: Revenue grew 2...
RLF Urges DexCom, Inc. (NASDAQ: DXCM) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of DexCom, Inc. (NASDAQ: DXCM)...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 21, 2024 in DexCom, Inc. Lawsuit – DXCM
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).
DexCom Q3 Preview: Walking On Eggshells With Its Channel Relationships
DexCom's Q2 earnings report was disastrous, revealing internal sales channel issues and competitive pressures, leading to a Hold rating and lowered price targets. The company's reliance on channel sal...
DXCM LEGAL NEWS: Suffer Losses on Your DexCom, Inc. Investment? Contact BFA Law before Expiration of Monday, October 21 Deadline (Nasdaq:DXCM)
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ:DXCM) and certain of the Comp...
DXCM LEGAL NOTICE: DexCom, Inc. Investors are Notified of Upcoming October 21 Court Deadline; Contact BFA Law if You Suffered Losses (Nasdaq:DXCM)
NEW YORK, NY / ACCESSWIRE / October 9, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ:DXCM) and certain of the Compa...